|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29.23 USD | +1.32% |
|
+0.14% | -9.50% |
| Apr. 11 | Harmony Biosciences, Bioprojet Enter Licensing Deal for Sleep Disorder Therapy | MT |
| Apr. 03 | Harmony Biosciences Begins Phase 3 Trial of Pitolisant to Treat Prader-Willi Syndrome Symptoms | MT |
Harmony Biosciences Holdings, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net income was USD 181.47 million compared to USD 34.6 million a year ago. Basic earnings per share from continuing operations was USD 3.07 compared to USD 0.6 a year ago.
Diluted earnings per share from continuing operations was USD 2.97 compared to USD 0.58 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -9.50% | 1.66B | |
| +25.61% | 660B | |
| +23.56% | 562B | |
| -5.24% | 358B | |
| +16.49% | 322B | |
| +8.28% | 297B | |
| +12.47% | 219B | |
| -9.86% | 196B | |
| +6.83% | 199B | |
| -8.75% | 149B |
HARMONY BIOSCIENCES HOLDINGS, INC. 
